Treatment planning consideration for prostate implants with the new linear RadioCoil 103Pd brachytherapy source.
Recently, various linear source models, for example, 103Pd RadioCoil, have been introduced to overcome the shortcomings of traditional "seed" type interstitial prostate brachytherapy implants, such as migration and clumping of the seeds. However, the existing prostate treatment-planning systems have not been updated to perform dose calculation for implants with linear sources greater than 1.0 cm in length. In these investigations, two new models are developed for 3D dose calculation for a prostate implant with linear brachytherapy sources using the commercially available treatment-planning systems. The proposed models are referred to as the linear-segmented source (LSS) model and the point-segmented source (PSS) model. The calculated dose distributions obtained by these models for a single linear source have been validated by their comparison with the Monte Carlo-simulated data. Moreover, these models were used to calculate the dose distributions for a multilinear source prostate implant, and the results were compared to "seed" type implants. The results of these investigations show that the LSS model better approximates the linear sources than the PSS model. Moreover, these models have shown a better approximation of the dose distribution from a linear source for 0.5 cm source segments as compared to 1.0 cm source segments. However, for the points close to the longitudinal axis of the source located outside the region bounded by the active length, both models show differences of approximately +/-15%. These deficiencies are attributed to the limitations of the TG43 formalism for elongated sources.
Meigooni
Ali S
AS
Department of Radiation Medicine, University of Kentucky Chandler Medical Center, 800 Rose Street, Lexington, Kentucky 40536-0084, USA. alimeig@uky.edu
Awan
Shahid B
SB
Rachabatthula
Venkata
V
Koona
Rafiq A
RA
D001918:Brachytherapy / Q000295:instrumentation* / Q000379:methods; D019544:Equipment Failure Analysis; D006801:Humans; D008297:Male; D010165:Palladium / Q000032:analysis / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D019736:Prostheses and Implants; D011868:Radioisotopes / Q000032:analysis / Q000627:therapeutic use*; D011874:Radiometry / Q000379:methods*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D011868:Radioisotopes; D010165:Palladium